122 related articles for article (PubMed ID: 16122884)
1. Metallothionein expression in invasive and in situ breast carcinomas.
Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
3. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
4. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast.
Gonzalez LO; Junquera S; del Casar JM; González L; Marín L; González-Reyes S; Andicoechea A; González-Fernández R; González JM; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2010 Jul; 41(7):980-9. PubMed ID: 20236691
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
8. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases.
Esposito NN; Dabbs DJ; Bhargava R
Am J Clin Pathol; 2009 Feb; 131(2):228-42. PubMed ID: 19141383
[TBL] [Abstract][Full Text] [Related]
9. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
El Sharkawy SL; Farrag AR
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking and metallothionein expression in invasive breast carcinomas.
Gallicchio L; Flaws JA; Sexton M; Ioffe OB
Toxicol Lett; 2004 Sep; 152(3):245-53. PubMed ID: 15331133
[TBL] [Abstract][Full Text] [Related]
11. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
12. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
13. Β-catenin expression in in situ and infiltrative ductal carcinomas of the breast.
Karabacak T; Eğılmez R; Arpaci RB; Pfeiffer ES
Turk Patoloji Derg; 2011; 27(3):185-8. PubMed ID: 21935866
[TBL] [Abstract][Full Text] [Related]
14. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma.
Jaffer S; Orta L; Sunkara S; Sabo E; Burstein DE
Hum Pathol; 2007 Jun; 38(6):864-70. PubMed ID: 17350670
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
17. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
18. Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation.
Surowiak P; Paluchowski P; Dziegiel P; Wysocka T; Wojnar A; Spaczyński M; Zabel M
Med Sci Monit; 2004 Aug; 10(8):BR300-5. PubMed ID: 15277992
[TBL] [Abstract][Full Text] [Related]
19. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
20. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
